Magnesium isoglycyrrhizinate in the treatment of chronic liver diseases

OBJECTIVE:To appraise the ability and assurance of Magnesium isoglycyrrhizinate in analysis of abiding alarmist diseases.
METHODS:It is a randomized, double-blind, multi-doses, alive biologic controlled, multi-center study. 480 able patients were about disconnected into accumulation A (180 patients), accumulation B (180 patients) or accumulation C (120 patients). Patients in accumulation A accustomed magnesium isoglycyrrhizinate 100 mg already daily. Patients in accumulation B accustomed magnesium isoglycyrrhizinate 150 mg already daily. Patients in accumulation C accustomed admixture glycyrrhizin 120 mg already daily. The analysis advance was 4 weeks. Patients were followed up 2 weeks afterwards the treatment. Patients visited already every 2 weeks. Clinical symptoms, ALT, AST were evaluated in all the patients afore treatment, at anniversary 2, at anniversary 4 and at 2 weeks afterwards afterwards treatment. The added alarmist action analysis was done afore analysis and at anniversary 4.
RESULTS:412 patients completed the abstraction according to the protocol,152 in accumulation A, 160 in accumulation B and 100 in accumulation C. ALT and AST akin were decidedly decreased in all groups at anniversary 2 and anniversary 4 (P < 0.05). The amount of ALT abatement is greater in accumulation B than in accumulation C at anniversary 2 (P < 0.01). The amount of ALT abatement was not cogent altered a part of three groups at anniversary 4 (P > 0.05). The ante of ALT advance at anniversary 4 in accumulation A, B, C were 92.59%, 91.76%, 88.29%, appropriately (P > 0.05). The ante of affection advance at anniversary 4 in accumulation A, B, C were 90.41%, 89.86%, 86.46% and 72.22%, 73.53%, 68.47%, appropriately (P > 0.05). No backsliding were begin in all three groups afterwards treatment. The amount of adverse accident in three groups was agnate (P > 0.05).